Evidence map›Paper›PMID 38361949›Full record

ArticleFrontiers in immunology2024

Age-dependent acquisition of IgG antibodies to

Melissa C Kapulu, Esther Muthumbi, Edward Otieno, Omar Rossi, Pietro Ferruzzi, Francesca Necchi, Alessandra Acquaviva, Laura B Martin, Benedict Orindi, Kennedy Mwai and 14 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
2.5field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. mBio · 2025
    Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors at 3 institutions in 4 countries.

Melissa C KapuluKEMRI-Wellcome Trust Programme, Kilifi, Kenya.
Esther MuthumbiKEMRI-Wellcome Trust Programme, Kilifi, Kenya.
Edward OtienoKEMRI-Wellcome Trust Programme, Kilifi, Kenya.
Omar RossiGSK Vaccines Institute for Global Health, Siena, Italy.
Pietro FerruzziGSK Vaccines Institute for Global Health, Siena, Italy.
Francesca NecchiGSK Vaccines Institute for Global Health, Siena, Italy.
Alessandra AcquavivaGSK Vaccines Institute for Global Health, Siena, Italy.
Laura B MartinGSK Vaccines Institute for Global Health, Siena, Italy.
Benedict OrindiKEMRI-Wellcome Trust Programme, Kilifi, Kenya.
Kennedy MwaiKEMRI-Wellcome Trust Programme, Kilifi, Kenya.
Hillary KibetKEMRI-Wellcome Trust Programme, Kilifi, Kenya.
Alfred MwanzuKEMRI-Wellcome Trust Programme, Kilifi, Kenya.
Godfrey M BigogoCentre for Global Health Research, Kenya Medical Research Institute, Kisumu, Kenya.
Jennifer R VeraniDivision of Global Health Protection, US Centers for Disease Control and Prevention, Nairobi, Kenya.
Cecilia MbaeCentre for Microbiology Research, Kenya Medical Research Institute, Nairobi, Kenya.
Christopher NyundoKEMRI-Wellcome Trust Programme, Kilifi, Kenya.
Charles N AgotiKEMRI-Wellcome Trust Programme, Kilifi, Kenya.
Usman Nasir NakakanaGSK Vaccines Institute for Global Health, Siena, Italy.
Valentino ContiGSK Vaccines Institute for Global Health, Siena, Italy.
Philip BejonKEMRI-Wellcome Trust Programme, Kilifi, Kenya.
Samuel KariukiCentre for Microbiology Research, Kenya Medical Research Institute, Nairobi, Kenya.
J Anthony G ScottKEMRI-Wellcome Trust Programme, Kilifi, Kenya.
Francesca MicoliGSK Vaccines Institute for Global Health, Siena, Italy.
Audino PoddaGSK Vaccines Institute for Global Health, Siena, Italy.
Kenya Medical Research Institute · KEToscana Life Sciences · ITCenters for Disease Control and Prevention · KE

Funding

Wellcome TrustWellcome Trust 218528
6 · The paper itself

Abstract

Background: Shigellosis mainly affects children under 5 years of age living in low- and middle-income countries, who are the target population for vaccination. There are, however, limited data available to define the appropriate timing for vaccine administration in this age group. Information on antibody responses following natural infection, proxy for exposure, could help guide vaccination strategies. Methods: We undertook a retrospective analysis of antibodies to five of the most prevalent Results: A total of 474 samples, one for each participant, were analyzed: Nairobi ( Conclusion: Children living in low- and middle-income settings such as Kenya are exposed to

Indexed as

Dysentery, BacillaryShigellaChildChild, PreschoolCross-Sectional StudiesFemaleHumansImmunoglobulin GInfantKenyaMaleRetrospective StudiesSeroepidemiologic StudiesSerogroupVaccinationImmunoglobulin GIgG antibodiesKenyasero-prevalenceserotypeShigella flexneriShigella sonnei

Identifiers

PMID38361949
PMCPMC10867106
OpenAlexW4391474031

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.